|
|
|
| . | Heinz Boller, Managing Director of Novartis
Italia, claimed he was satisfied with last years' results. “The turnover
grew by 5% and reached the overall figure of 1,626 billion lira”.
Boller commented the results and claimed that “growth in Italy's pharmaceutical field was not as good as we estimated because we did not receive the approval to launch new products”. |
 |
 |